Oncology in Clinical Practice

Strona główna
Polska
Warsaw
Oncology in Clinical Practice

Dane kontaktowe, mapa i wskazówki, formularz kontaktowy, godziny otwarcia, usługi, oceny, zdjęcia, filmy i ogłoszenia od Oncology in Clinical Practice, Zdrowie i medycyna, Ulica Roentgena 5, Warsaw.

27/02/2026

A retrospective observational study in breast cancer patients receiving FEC chemotherapy found predictors of oral mucositis (older age, more chemotherapy cycles, NSAID use, and mucoprotective agent use) and dysgeusia/taste changes (lower albumin levels). Knowing these risk factors may help optimize supportive care, reduce oral complications, and avoid serious adverse events during systemic treatment.

Authors: Yuko Kanbayashi, Tetsuya Taguchi, Takeshi Ishikawa, Koichi Takayama

25/02/2026

A prospective observational study in 60 women receiving chemotherapy after breast cancer surgery found that more walking and moderate-intensity activity were associated with better physical and psychological quality of life, while more sedentary time was linked to lower well-being. This suggests that staying active can be a simple yet powerful part of supportive care.

Authors: Tomasz Jurys, Joanna Grupińska, Marika Wlazło, Magdalena Budzyń, Ewa Malchrowicz-Mośko, Mateusz Grajek

24/02/2026

Extraskeletal myxoid chondrosarcoma is an ultra-rare soft tissue sarcoma with a high risk of lung metastases. In two cases, repeated metastasectomies temporarily controlled the disease, but recurrences were common, and chemotherapy showed limited benefit.
Authors: Julia Wąż, Piotr Remiszewski, Mateusz Spałek, Sławomir Falkowski, Piotr Rutkowski, Anna M. Czarnecka

$Moderately hypofractionated radiotherapy (HF-M) offers an effective, shorter treatment for prostate cancer. In a retrosp...$

18/02/2026

Moderately hypofractionated radiotherapy (HF-M) offers an effective, shorter treatment for prostate cancer. In a retrospective cohort of 143 patients (mostly high-risk), HF-M delivered good biochemical control (median follow-up PSA 0.06 ng/mL) with manageable toxicity (acute toxicity 25.17%, late toxicity 37.06%; no grade 3–4 GU/GI events reported). Patient-reported outcomes highlighted quality-of-life impacts, supporting its use in everyday practice.

Authors: Javier Cifuentes-Quin, Yiselle García-Montañez, Alexandra Hurtado-Ortiz, Jhonatan Cruz, Luis Olarte-Licht, Alejandra Mendoza-Monsalve, Maricel Licht-Ardila, Edgar Fabián Manrique-Hernández

17/02/2026

VEGFR-TKIs remain a cornerstone in treating metastatic renal cell carcinoma (mRCC), particularly in favorable-risk patients, when immunotherapy is contraindicated (or not accessible), and in subsequent lines of therapy. Understanding their side-effect profiles and proactively managing adverse events can improve tolerance and outcomes, supporting individualized treatment choices. This recent narrative review summarizes key differences in VEGFR-TKI adverse events and discusses their potential prognostic impact—useful knowledge for everyday practice.

Authors: Piotr Domański, Szymon Staneta, Weronika Fortuniak, Adam Kobiernik, Mateusz Piętak, Barbara Kruczyk, Karol Grela, Mikołaj Sobczyński, Beata Janas, Elżbieta Sarnowska, Jakub Kucharz

16/02/2026

NTRK gene fusions, though rare, are powerful therapeutic targets—especially in CNS tumors. TRK inhibitors like larotrectinib, entrectinib, and newer agents (e.g., repotrectinib; taletrectinib in trials) show response rates up to ~80% and can cross the blood–brain barrier, transforming treatment options. Recent advances in the management of NTRK fusions were discussed in this review

Authors: Julia Piekarz, Natalia Picheta, Jakub Pobideł, Katarzyna Szklener

13/02/2026

Superior vena cava syndrome occurs in a small subset of SCLC patients and is associated with tumor size and right-sided, upper-lobe location. Importantly, the syndrome itself does not appear to worsen overall survival, as pointed out in a recent study

Authors: Faruk Tas, Akin Ozturk, Kayhan Erturk

11/02/2026

Beyond BRCA1 and BRCA2, this case report describes a family in which a pathogenic PALB2 deletion co-occurs with a CHEK2 p.Ile157Thr variant (uncertain/low-risk) in a woman with breast cancer and a broader family history of cancer—highlighting why germline testing and genetic counselling matter for tailored surveillance and prevention.

Authors: Natalia Krzyżanowska, Paweł Krawczyk, Kamila Wojas-Krawczyk, Łukasz Gajek, Adrian Obara
Read the full text at: https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/108058

09/02/2026

With rapidly evolving cancer therapies, supportive care must keep pace. This experts’ opinion on the use of granulocyte colony-stimulating factors outlines current guidelines and real-world practice, offering practical recommendations to help prevent febrile neutropenia and support the safe delivery of systemic treatments.

Authors: Rafał Ł. Czyżykowski, Piotr Chilczuk, Elżbieta Iskierka-Jażdżewska, Leszek Kraj, Maciej Krzakowski, Tomasz Kubiatowski, Łukasz Kwinta, Marta Olszyna-Serementa, Katarzyna Pogoda, Bartosz Puła, Barbara Radecka, Piotr Wysocki, Piotr Potemski

04/02/2026

Neoadjuvant immunotherapy is changing the treatment landscape for patients with resectable NSCLC. This comprehensive review provides an overview of current advances, considerations for special patient populations, and perspectives for future developments.

Authors: Ahmed Sohaib, Ziad Samir, Ahlam Alqahtani, Fahad Alshahrani, Samar Hosny, Mohamed Alhefny

03/02/2026

In this study of 102 oncology patients, greater emotional and instrumental social support was associated with lower anxiety and depression. Active coping and seeking support were also linked to better outcomes, highlighting the importance of psychological and social care alongside medical treatment.

Authors: Julia W. Dąbrowska-Ilnicka, Katarzyna A. Milska-Musa

29/01/2026

Can routine blood tests help predict outcomes in small cell lung cancer? This retrospective study of 378 SCLC patients found that thrombocytosis in limited-disease SCLC (LD-SCLC) and anemia in extended-disease SCLC (ED-SCLC) were linked to poorer response to chemotherapy, highlighting the potential predictive/prognostic value of baseline complete blood count (CBC) parameters.

Authors: Faruk Tas, Akin Ozturk, Kayhan Erturk

Adres

Ulica Roentgena 5
Warsaw
02-781

Strona Internetowa

https://journals.viamedica.pl/oncology_in_clinical_practice, https://www.researchgate.net/journal/Oncology-in-Clinical-P

Ostrzeżenia

Bądź na bieżąco i daj nam wysłać e-mail, gdy Oncology in Clinical Practice umieści wiadomości i promocje. Twój adres e-mail nie zostanie wykorzystany do żadnego innego celu i możesz zrezygnować z subskrypcji w dowolnym momencie.

Skontaktuj Się Z Praktyka

Wyślij wiadomość do Oncology in Clinical Practice:

Skróty

Chcesz aby twoja praktyka była na górze listy Klinika w Warsaw?

Udostępnij

Kategoria

Zdrowie i medycyna